Baystreet Staff - Wednesday, October 10, 2007 Vasogen Inc. 01:00 PM EST - Vasogen Inc. : said it will aggressively pursue partnerships and financing to ensure it's properly funded to complete a new clinical trial for its lead product. Vasogen Inc. shares T.VAS are trading down 1 cent at $2.22.